Liraglutide products; labels read November 8, 2026 (Saxenda revised 02/2026, Victoza revised 05/2025); generic approval dates from Drugs@FDA
SaxendaVictozaGeneric liraglutide
UseWeight management: adults; ages 12+ over 60 kg with obesityType 2 diabetes (ages 10+); CV risk reduction in adults with heart diseaseFollows the brand it references; labels we read cover either the Victoza or the Saxenda use
ScheduleOnce dailyOnce dailyOnce daily
Doses0.6 mg rising weekly to 3 mg0.6 mg, then 1.2 mg, up to 1.8 mgSame pen strength (18 mg/3 mL)
First approvedDecember 23, 2014January 25, 2010December 23, 2024 (Victoza reference); August 27, 2025 (first Saxenda reference)

How is liraglutide different from weekly GLP-1 drugs?

The main practical difference is frequency: liraglutide is injected every day, while semaglutide, tirzepatide and dulaglutide are weekly. Liraglutide was also the first of these molecules to reach the U.S. market, in 2010.

Both liraglutide brands use the same 6 mg/mL pen, which delivers doses from 0.6 mg up. A daily schedule means more injections but also a shorter gap if you miss one. Both labels say to skip a missed dose and resume the next day, and to restart at 0.6 mg if more than 3 days have passed. For how the newer weekly drug compares, see semaglutide.

How is Saxenda dosed?

Saxenda starts at 0.6 mg daily and rises by 0.6 mg each week until it reaches 3 mg in week 5. For adults, lower doses are for titration only.

The Wegovy, Zepbound and Foundayo labels we read have no equivalent weight-based stopping rule, so this 16-week check gives Saxenda users and their prescribers an unusually clear point to decide whether to continue.

What did the SCALE trial show?

SCALE Obesity and Prediabetes enrolled 3,731 adults without type 2 diabetes. At 56 weeks, those on liraglutide 3 mg lost a mean 8.4 kg versus 2.8 kg on placebo, per the published paper.

In that trial, 63.2% on liraglutide lost at least 5% of body weight, versus 27.1% on placebo, and 33.1% versus 10.6% lost more than 10%. The Saxenda label reports the same trial (its Study 1) in percentage terms: a mean 7.4% reduction versus 3.0% on placebo. The paper and the label use different units and different analyses, so the figures are not interchangeable; name the source whenever you quote either one.

The most common side effects in Saxenda's adult trials were nausea (39.3% vs 13.8% on placebo), diarrhea (20.9% vs 9.9%), constipation (19.4% vs 8.5%) and vomiting (15.7% vs 3.9%).

What about Victoza and heart risk?

Victoza's second indication comes from LEADER, which the label describes as a trial of 9,340 adults with type 2 diabetes and atherosclerotic heart disease. Major cardiovascular events occurred in 13.0% on Victoza versus 14.9% on placebo, a hazard ratio of 0.87 (95% CI 0.78 to 0.97).

Victoza starts at 0.6 mg daily for a week, which the label says is not effective for blood sugar in adults, then 1.2 mg, with an optional rise to 1.8 mg. In children 10 and older, the dose rises in 0.6 mg steps to the same 1.8 mg maximum. For the broader diabetes picture, see GLP-1 drugs and type 2 diabetes.

Is generic liraglutide available?

Yes. FDA approved the first generic referencing Victoza on December 23, 2024, from Hikma, noting that liraglutide was in shortage at the time.

Drugs@FDA lists the first Saxenda-referencing generic, from Teva, approved August 27, 2025; the Teva label on DailyMed carries Saxenda's weight-management indication. When we queried Drugs@FDA on November 8, 2026, approved liraglutide generic applications were listed for Hikma, Emerge, Lupin, Teva, Orbicular, Biocon, Fresenius Kabi, Mylan and Sandoz. Approval does not guarantee a product is on pharmacy shelves, and some of these may reference Victoza rather than Saxenda.

Is compounded liraglutide on the table?

Compounded liraglutide is not FDA-approved. FDA's April 30, 2026 proposal not to place drugs on the 503B bulks list covered liraglutide along with semaglutide and tirzepatide; the comment period was extended to July 30, 2026, and we found no final decision as of November 20, 2026. With FDA-approved generics now listed, the case for compounded liraglutide is weaker than it was during the shortage. Our 503A vs 503B guide explains what the bulks list controls.

What warnings apply to all liraglutide products?

Every liraglutide label we read carries the boxed warning about thyroid C-cell tumors and a contraindication for people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Labels also warn about pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration and serious allergic reactions. Saxenda's label says not to combine it with other liraglutide products or any other GLP-1 receptor agonist. For a side-by-side of every brand, see the GLP-1 medications hub.

Frequently asked questions

Is Saxenda the same as Victoza?

Both contain liraglutide in the same 6 mg/mL pen, but they have different labels. Saxenda is approved for weight management and is dosed up to 3 mg daily. Victoza is approved for type 2 diabetes and heart risk reduction in adults with type 2 diabetes and heart disease, up to 1.8 mg daily. The Saxenda label says not to combine liraglutide products.

When should Saxenda be stopped if it is not working?

The Saxenda label tells prescribers to evaluate adults 16 weeks after starting and to discontinue if the patient has not lost at least 4% of baseline body weight, because clinically meaningful weight loss is then unlikely with continued treatment. It also says adults who cannot tolerate the 3 mg dose should stop. Pediatric patients have separate criteria.

When was generic Saxenda approved?

Drugs@FDA lists the first generic liraglutide referencing Saxenda, from Teva, as approved on August 27, 2025, and Teva's label on DailyMed carries Saxenda's weight-management indication. The first generic referencing Victoza, from Hikma, was approved earlier, on December 23, 2024. Approval dates do not tell you current pharmacy availability or price.

How much weight did people lose on liraglutide in trials?

In SCALE Obesity and Prediabetes, 3,731 adults without type 2 diabetes received liraglutide 3 mg or placebo for 56 weeks. Mean weight loss was 8.4 kg versus 2.8 kg, and 63.2% versus 27.1% lost at least 5% of their weight. The Saxenda label reports the same study as a 7.4% versus 3.0% mean reduction.

Is liraglutide covered by the 503B proposal?

Yes. FDA's April 30, 2026 proposal not to add drugs to the 503B bulks list named liraglutide along with semaglutide and tirzepatide. The comment period was extended to July 30, 2026, and we found no final decision as of November 20, 2026. Compounded liraglutide is not FDA-approved either way.

Sources

  1. FDA label (DailyMed): Saxenda prescribing information — label revised 02/2026; sections 1, 2, 3, 6.1, 14 read 2026-11-08
  2. FDA label (DailyMed): Victoza prescribing information — label revised 05/2025 (SPL effective October 14, 2025); read 2026-11-08
  3. FDA: FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes — press release December 23, 2024; read 2026-11-08
  4. Drugs@FDA (openFDA): liraglutide applications, incl. ANDA 214568 (Teva, approved 2025-08-27) and ANDA 215503 (Hikma, approved 2024-12-23) — queried 2026-11-08; Teva generic label (DailyMed setid 625ac780-70a9-41e4-a892-bcba0f803f1c) read 2026-11-08
  5. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med 2015;373:11-22 — published July 2, 2015; abstract read 2026-11-08
  6. FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list — announced 2026-04-30; no final decision found as of 2026-10-15

Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.

Check NexLife's plans and state availability → See the price index

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.